Impact of Body Mass Index on Survival of Metastatic Renal Cancer

Main Article Content

Jose Javier Salgado Plonski
Sergio Fernández-Pello
Laura Rúger Jiménez
Iván González Rodríguez
Laura Alonso Calvar
Luis Rodríguez Villamil

Keywords

body mass index, carcinoma, metastatic, renal, survival

Abstract

Obesity has been established as a risk factor for renal cell carcinoma (RCC). Recently, studies have described obesity as a probable protecting factor in the metastatic stage of RCC. In this study, we assessed the relationship between body mass index (BMI) and overall survival in patients under systemic therapy.


The correlation between BMI and overall median survival was studied in 76 patients diagnosed with metastatic RCC under systemic therapy. The groups were divided into overweight and obesity (BMI > 25 kg/m2) and underweight or normal (BMI < 25 kg/m2). Statistical analysis was performed using the Cox regression model adjusted by gender.


A total of 76 patients were studied: 16 women (21%) and 60 men (79%). The median BMI was 27.96 kg/m2; 24 patients (31.6%) had low BMI and 52 (68.4%) had high BMI. Median overall survival in the group with BMI > 25 kg/m2 was 17 months (95% confidence interval [CI]: 13–34 months), while in the group with BMI ≤ 25 kg/m2, it was 14 months (95% CI: 8–20 months). When adjusted by gender, the group with BMI > 25 kg/m2 presented a hazards ratio of 0.54 (95% CI: 0.30–0.96), P = 0.044 (Log Rank).


A high BMI significantly acts as a protecting factor. We observed an increased overall survival of overweight and obese patients within the context of metastatic RCC under systemic treatment. These data confirm the findings published in other studies that suggest the role of lipid metabolism in this type of tumors.

Abstract 512 | PDF Downloads 443 HTML Downloads 138 XML Downloads 65

References

1. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91. https://doi.org/10.1038/nrc1408
2. Kim LH, Doan P, He Y, Lau HM, Pleass H, Patel MI. A systematic review and meta-analysis of the significance of body mass index on kidney cancer outcomes. J Urol. 2021;205(2):346–55. https://doi.org/10.1097/JU.0000000000001377
3. Guerre-Millo M. Adipose tissue hormones. J Endocrinol Invest. 2002;25(10):855–61. https://doi.org/10.1007/BF03344048
4. Fràter-Schröder M, Risau W, Hallmann R, Gautschi P, Böhlen  P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA. 1987;84(15):5277–81. https://doi.org/10.1073/pnas.84.15.5277
5. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced anti angiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101(8):2476–81. https://doi.org/10.1073/pnas.0308671100
6. Rajala MW, Scherer PE. Mini-review: The adipocyte—At the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144(9):3765–73. https://doi.org/10.1210/en.2003-0580
7. Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, et al. Body mass index and survival in patients with renal cell carcinoma: A clinical-based cohort and meta-analysis. Int J Cancer. 2013;132(3):625–34. https://doi.org/10.1002/ijc.27639
8. Ito R, Narita S, Huang M, Nara T, Numakura K, Takayama K, et al. The impact of obesity and adiponectin signaling in patients with renal cell carcinoma: A potential mechanism for the “obesity paradox.” PLoS One. 2017;12(2):e0171615. https://doi.org/10.1371/journal.pone.0171615
9. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941–6. https://doi.org/10.1038/90984
10. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010;6(4):551–62. https://doi.org/10.2217/fon.10.11
11. Albiges L, Xie W, Lee J-L, Rini B, Srinivas S, Bjarnason G, et al. The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium. J Clin Oncol. 2014;32:4576. https://doi.org/10.1200/jco.2014.32.15_suppl.4576
12. Albiges L, Hakimi A, Lin X, Simantov R, Zabor E, Jacobsen Skanderup A, et al. The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of under-lying biology from The Cancer Genome Atlas. J Clin Oncol. 2015;33:405. https://doi.org/10.1200/jco.2015.33.7_suppl.405
13. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol. 2009;27:5794–99. https://doi.org/10.1200/jco.2009.27.15_suppl.5041
14. Sanchez A, Furberg H, Kuo F, Vuong L, Ged Y, Patil S, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: A cohort study. Lancet Oncol. 2020;21(2):283–93. https://doi.org/10.1016/S1470-2045(19)30797-1
15. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454–63. https://doi.org/10.1200/JCO.2004.06.132
16. Santoni M, Cortellini A, Buti S. Unlocking the secret of the obesity paradox in renal tumours. Lancet Oncol. 2020;21(2): 194–6. https://doi.org/10.1016/S1470-2045(19)30783-1
17. De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res. 2019;25(13):3839–46. https://doi.org/10.1158/1078-0432.CCR-18-3661